



# Rapid assessment of the impact of the COVID-19 pandemic on people who inject drugs in Montreal, Canada



Nanor Minoyan PhD Candidate

Centre de Recherche du CHUM / École de Santé Publique, Université de Montréal

Co-authors: Stine Bordier Høj, Dragos Vlad, Julie Bruneau, Sarah Larney



## Acknowledgements

This research was conducted in the traditional and unceded territory of the Kanien'keha:ka (Mohawk) and the Abenaki and Wabanaki confederation

We would like to thank the people who inject drugs who generously participated in this research



## Disclosures

- Julie Bruneau: Research grants from Gilead Sciences and Abbvie (unrelated to the present work), Canada Research Chair in Addiction Medicine, advisor fees from Gilead Sciences and Abbvie (unrelated to the present work)
- Sarah Larney: untied educational grant funding from Indivior.



## Background: COVID-19 & PWID

- The COVID-19 pandemic has had disproportionate impacts on vulnerable populations
- People who inject drugs (PWID)
  - † risk of infection / mortality
  - † risk of indirect harms of measures to curb viral spread



# Objectives

#### Rapid assessment study:

• Examine the impacts of the COVID-19 pandemic on the health and well-being of people who use drugs (3 Canadian sites)

### This analysis:

 Impacts on access to housing, health services, and harm reduction among people who inject drugs (PWID) in Montreal



## Questionnaire

- Informed by an existing review of health needs assessments in disaster contexts<sup>1</sup>
- Most questions assessed a change since the pandemic was declared a health emergency in the province of Quebec, on March 13, 2020



## Recruitment

Active participants of an existing cohort study of PWID

May-June 2020





eligibility criteria: age ≥18; past-6-month injection drug use

Sep-Dec 2020





# **Analyses**

• Descriptive statistics, restricted to people reporting past-six-month injection drug use at the study visit.



# Participant characteristics


	Total (N=94)	
	n	%
Gender		
Male	67	71%
Female	26	28%
Other	1	1%
Ethnicity		
White	86	91%
Indigenous	5	5%
Other / refusal	3	3%
Recent unstable housing <sup>1</sup>	26	28%

<sup>&</sup>lt;sup>1</sup>Past six months in May-June, 6 months prior to the pandemic in Sep-Dec.



# Housing

27% Experienced change in living situation since (n=25) the start of the health emergency





# Housing

13% reported that they had become homeless as a result of the health emergency

91% of the unstably housed subset (n=23¹) reported that (n=21) finding a place to stay had become more difficult




## Opioid agonist treatment (OAT)

- 50 participants (53% of the sample) were on OAT at the time of the study interview
  - 19 (38%) had discussed strategies to avoid treatment disruptions with provider(s)
  - 10 (20%) had missed ≥1 dose due to service disruptions




## Satisfaction

With how medical team adapted to provide treatment during the health emergency...



## Health services





## Addiction / harm reduction services

#### Attempts to access since the start of the health emergency

Drug or alcohol treatment



11% (n=9)



23% (95% able to access)

Needle-syringe programs

79% (93% able to access)



45% (71% able to access)



#### Discussion

- Findings suggest mixed impacts of the COVID-19 pandemic on PWID's ability to meet essential needs and services
- Access to sterile injection material seemed adequate during the assessed period; impacts on access to other harm reductions were less clear.
- Negative impacts on access to healthcare services may undermine overall health of PWID and set back HCV elimination efforts
- Limited access to housing may increase exposure to high risk environments and exacerbate existing harms among the most vulnerable; responses should be tailored to reach this group
- Continued monitoring is warranted



## Limitations

- Convenience sample
- Study is a snapshot of perceptions / experiences up to December 2020
  - 2021 curfew not captured

## Collaborators & Funding

#### Research team / collaborators:

Isabelle Boisvert

Catherine Boucher

Sira Diarra

Katia Dumont

Didier Jutras-Aswad

Rania Khemiri

Iuliia Makarenko

Valérie Martel-Laferrière

Manuela Mbacfou Temgoua

Gabriel Morier

Molly Nuckle

Valeria Saavedra

Aïssata Sako

Marie-Eve Turcotte

Geng Zang

Camille Zolopa

**HEPCO** cohort team



INITIATIVE CANADIENNE
DE RECHERCHE
EN ABUS DE SUBSTANCE



Contact: nanor.minoyan@umontreal.ca

Toronto team: Dan Werb, Ayden Scheim, Ruby Sniderman, Zachary Bouck Vancouver team: Kora DeBeck, Ekaterina Nosova, Kanna Hayashi, M-J Milloy

